Capstone Investment Advisors
NVCR icon

Capstone Investment Advisors’s NovoCure NVCR Stock Holding History

Capstone Investment Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-16,464
Closed -$213K – 1917
2025
Q3 		$213K Buy
+16,464
New +$220K ﹤0.01% 1798
2024
Q2 		– Sell
-25,835
Closed -$404K – 2346
2024
Q1 		$404K Buy
+25,835
New +$380K ﹤0.01% 1674

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Capstone Investment Advisors's NVCR Position: Q4 2025 in Review

Capstone Investment Advisors sold out of NovoCure (NVCR) in Q4 2025, closing a stake of 16,464 shares — an estimated $213K sold.

Capstone Investment Advisors first reported a position in NVCR in Q1 2024 and held it in 2 quarters. The position peaked at $404K in Q1 2024. 238 funds tracked by Wall St. Rank hold NVCR as of Q4 2025.

  • Capstone Investment Advisors reported no remaining NovoCure position as of Q4 2025 after selling out during the quarter.
  • Capstone Investment Advisors sold 16,464 NovoCure shares in Q4 2025, an estimated $213K.
  • Capstone Investment Advisors first reported a position in NovoCure in Q1 2024 and held it in 2 quarters.
  • Capstone Investment Advisors's NovoCure position peaked at $404K in Q1 2024.
  • 238 funds tracked by Wall St. Rank held NovoCure as of Q4 2025.

Based on Capstone Investment Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.